Entera Bio Stock

Entera Bio Stock-Based Compensation

The Stock-Based Compensation (SBC) of Entera Bio (ENTX) as of Aug 16, 2026 is 2.75 M USD. In the previous year, Stock-Based Compensation (SBC) was 2.56 M USD — a change of 7.59% (higher).

Stock-Based Compensation

2.75 MUSD

YoY

7.59%

Last updated:

Stock-Based Compensation (SBC) of Entera Bio is 2026 2.75 M USD. Stock-Based Compensation (SBC) of Entera Bio was 2025 2.56 M USD. It decreases by 7.59% higher compared to the previous year.
Access this data via the Eulerpool API

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

Stock-Based Compensation (SBC) of Entera Bio is 2.75 M USD in 2026.

Stock-Based Compensation (SBC) of Entera Bio changed from 2.56 M USD to 2.75 M USD, representing a 7.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Entera Bio since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Entera Bio historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Entera Bio

All Key Metrics — Entera Bio